Budesonide/salmeterol is an innovative LABA/ICS combination developed by Laboratoires SMB used in the treatment in asthma.
It combines the safest LABA with the most efficient ICS.
Our patented Budesonide/Salmeterol fixed dose combination product is proposed as capsules containing dry powder for inhalation in the strengths 120/20µg and 240/20µg in HPMC capsules to be used with the Axahaler® DPI device. Additional dosage will be included for the pediatric population.
Clinical studies : full clinical development including phase II and phase III clinical studies. On-going pediatric clinical study.
Publications : Todor A. Popov, Sophie De Niet & Francis Vanderbist. Budesonide/ salmeterol in fixed-dose combination for the treatment of asthma. Expert Review of Respiratory Medicine, 2016 Feb;10(2):113-25.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy Policy